Catalent

Catalent is a premier, universally recognized global provider of advanced delivery technologies, development, and robust manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. Headquartered in Somerset, New Jersey, Catalent operates a vast, highly resilient global footprint with over 50 advanced facilities strategically located across five continents, ensuring robust supply chains for its thousands of partners.

The company is perhaps best known historically for its proprietary Zydis® fast-dissolving tablet technology and unparalleled advanced softgel manufacturing capabilities, holding a dominant global market position in specialized oral dose delivery. Beyond its mastery of oral solid doses, Catalent has aggressively and successfully expanded its biologics and advanced therapeutics portfolio through massive investments and strategic acquisitions.

They now offer highly comprehensive, end-to-end services encompassing mammalian biomanufacturing, complex sterile fill-finish operations, and cutting-edge viral vector and plasmid DNA manufacturing specifically tailored for next-generation gene therapies.

Catalent plays a critical, often behind-the-scenes role in the global pharmaceutical industry, having expertly helped develop, formulate, and launch thousands of critical products, including numerous high-profile COVID-19 vaccines and advanced therapeutics for major global pharma clients. Their unique ability to comprehensively handle complex formulation challenges, rapidly scale production, and navigate highly stringent global regulatory environments makes Catalent a profoundly trusted CDMO partner.